Laser Interstitial Thermal Therapy Extends Survival in Glioblastoma When Tumor Ablation Exceeds 91% and Treatment Occurs Early
核心洞察
A prospective multicenter analysis of 787 brain tumor patients found that the extent of tumor ablation and timing of laser interstitial thermal therapy (LITT) significantly influence survival outcomes.
Glioblastoma (搜索) patients with at least 91% of their tumor cleared by the laser survived 2.1 years from diagnosis, compared with roughly 1.5 years for standard open surgical resection.
The minimally invasive NeuroBlate (搜索) procedure requires only a single-stitch incision, limits average hospital stay to 32 hours, and preserves day-to-day quality of life.
For patients facing glioblastoma (搜索), one of the most aggressive and devastating forms of brain cancer, the standard path forward has long meant invasive open-skull surgery and a daunting prognosis. Now, an analysis of patient outcomes led by researchers at Washington University School of Medicine in St. Louis has identified procedural factors that may enhance the benefits of a minimally invasive laser treatment, revealing that the extent of tumor removal and the timing of treatment extend survival.
The analysis, published in the Journal of Clinical Oncology, focused on 787 brain tumor patients included in a prospective multicenter study that tracked patients for up to five years after undergoing the minimally invasive laser procedure. WashU Medicine led the study at Siteman Cancer Centre and 24 other locations across the U.S.
"Our goal is to both extend the survival of our brain tumor patients and improve the quality of their lives," said the study's principal investigator and lead author Eric C. Leuthardt, MD, the Shi Hui Huang Professor of Neurological Surgery at WashU Medicine and chief of the Division of Neurotechnology. "This analysis identifies the factors that lead to the best outcomes. This critical new information will help us find opportunities for patients to benefit the most from this therapy."
How Laser Interstitial Thermal Therapy Works
Patients diagnosed with glioblastoma (搜索) and other brain tumors typically undergo invasive surgery that involves temporarily removing part of the skull to remove the tumor, often followed by both chemotherapy and radiation. For those with tumors that are difficult or impossible to remove with open surgery, doctors often treat the cancer with a less-invasive intervention known as laser interstitial thermal therapy, or LITT.
In this procedure, neurosurgeons drill a tiny hole in the skull and insert a robotically controlled laser probe guided by real-time MRI that helps steer the probe through the brain to the tumor on a path that avoids healthy tissue damage. Once inside the tumor, the laser emits heat that kills the surrounding tumor cells. The surgical tool, NeuroBlate (搜索), was developed by Monteris Medical, a neurosurgical technology company that funded the study. NeuroBlate was cleared for marketing by the U.S. Food and Drug Administration in 2009.
Extent of Ablation and Timing Drive Survival
Among patients with inoperable or recurrent tumors, the researchers found that how much of the tumor is destroyed by the laser is an important factor in how long a patient survives, especially for those with newly diagnosed glioblastoma (搜索). Their analysis showed that glioblastoma patients who had at least 91% of their tumor cleared survived 2.1 years from diagnosis.
Because survival with standard open surgical resection is approximately 1.5 years, this provides essential information for considering NeuroBlate (搜索) as a tool that can also be used to treat these tumors up front. However, experts have cautioned that this should not be interpreted as proof that laser therapy provides better survival than standard surgery.
Beyond glioblastomas, the analysis delivered insights for treating brain metastases (搜索)—cancers that have spread to the brain from other parts of the body—after prior radiation therapy. The data revealed a survival advantage for patients who received laser therapy when the tumors were still small. This insight re-evaluates the common practice of watchful waiting, in which clinicians may wait several imaging cycles to confirm tumor growth. Treating earlier, when the tumor is smaller, yields better outcomes than waiting for the tumor to grow.
Impact on Patient Experience
Aside from extending lives, the study confirmed that the laser treatment impacts the patient experience. Traditional brain surgery requires partial, temporary skull removal and weeks of recovery. In contrast, the laser procedure requires only a single-stitch incision a few millimetres wide.
The researchers, including WashU Medicine physician-scientist Albert H. Kim, MD, PhD, the August A. Busch, Jr. Professor of Neurological Surgery and director of The Brain Tumour Centre at Siteman Cancer Centre, showed that the procedure is well-tolerated, maintains a patient's day-to-day quality of life, and limits the average hospital stay to just 32 hours. Patients recovered quickly and most avoided intensive care and readmission. The procedure also reduced the need for anti-seizure medication compared to before the surgery.
"We are shifting the entire framework of how we handle brain tumors," said Leuthardt. "When patients are told they have months to live, having the option of a low-risk procedure that gets them back home to their families in just over a day is profoundly meaningful."
Clinical Significance
Dr. Amar Rewari, chief of radiation oncology at Luminis Health and an adjunct assistant professor at the Johns Hopkins University School of Medicine, told Newsweek the study reveals "important information about how and when we may be able to use [the laser treatment] most effectively."
"For patients with tumors that are difficult to reach surgically, or for whom another open brain operation carries substantial risk, having a minimally invasive option is particularly attractive," he added. "With glioblastoma (搜索), we unfortunately still do not have anything approaching a cure for most patients, so improvements in both survival and quality of life are meaningful."
For decades, WashU Medicine and Barnes-Jewish Hospital have pioneered laser neurosurgery. In 2010, Leuthardt performed the nation's first laser interstitial thermal therapy for a brain metastasis at Barnes-Jewish Hospital following the FDA clearance of the NeuroBlate (搜索) surgical tool. This milestone was enabled by early investments from BJC HealthCare in intraoperative MRI capabilities, allowing surgeons to see tissue in real time and make more precise decisions during the operation.